Edition:
India

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

223.60CHF
22 Jun 2018
Change (% chg)

CHF4.00 (+1.82%)
Prev Close
CHF219.60
Open
CHF220.00
Day's High
CHF224.40
Day's Low
CHF219.60
Volume
83,928
Avg. Vol
28,793
52-wk High
CHF256.75
52-wk Low
CHF209.40

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.97
Market Cap(Mil.): CHF214,033.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.31

Financials

  RO.S Industry Sector
P/E (TTM): 22.03 30.95 32.74
EPS (TTM): 11.25 -- --
ROI: 20.46 14.84 14.38
ROE: 46.88 16.34 16.08

Deals of the day-Mergers and acquisitions

June 19 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

20 Jun 2018

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

ZURICH/LONDON Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.

19 Jun 2018

UPDATE 2-Roche pays $2.4 bln for rest of cancer expert Foundation Medicine

* Echoes past biotech buy-outs at Flat Iron and Genentech (Adds more on personalised cancer care, analyst comment)

19 Jun 2018

Roche to pay $2.4 bln to buy rest of Foundation Medicine

ZURICH, June 19 Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI), valuing the U.S. genomic profiling group at $5.3 billion, the partners said on Tuesday.

19 Jun 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

18 Jun 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH, June 18 A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

18 Jun 2018

Sanofi says on track to regain solid position in cancer drugs

PARIS Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.

13 Jun 2018

UPDATE 1-Sanofi says on track to regain solid position in cancer drugs

PARIS, June 13 Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.

13 Jun 2018

German stocks - Factors to watch on June 13

FRANKFURT/BERLIN, June 13 The following are some of the factors that may move German stocks on Wednesday:

13 Jun 2018

Vontobel aims to boost targets after Notenstein takeover

ZURICH, June 11 Swiss bank Vontobel aims to increase its 2020 return on equity target after its 700 million Swiss franc ($710 million)takeover of private bank Notenstein La Roche, finance chief Martin Sieg told an investor presentation on Monday.

11 Jun 2018

Earnings vs. Estimates